Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes
Main finding · Risk of progression to ESKDResult — go to the resultFold increased risk 1.91 95% CI 1.04–3.50Authors' conclusion
Urine LRG1, a TGF-β signaling modulator, predicts risk of progression to ESKD independently of clinical risk factors in patients with type 2 diabetes, suggesting that it may be a novel factor involved in the pathophysiological pathway leading to kidney disease progression.
Study context
- Population
- Participants with T2D and estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m², recruited from a regional hospital and a primary care facility
- Participants
- 1,837 participants
- Exposure
- Highest vs lowest tertile of baseline urine LRG1
- Outcome
- ESKD: progression to sustained eGFR <15 mL/min/1.73 m², dialysis, or death from renal causes
- Follow-up
- Median 8.6 (IQR 5.8-9.6) years
Main finding
Risk of progression to ESKD
Fold increased risk
1.91
95% CI 1.04–3.50
As reported in the abstract
- Incident end-stage kidney disease (ESKD) events
- 134
- Adjusted risk of ESKD per 1 SD increment in urine LRG1 (fold)
- 1.53 (95% CI 1.19-1.98)
Observational data: associations, not effects.
Further findings
- Urine LRG1 was associated with rapid kidney function decline and progression to macroalbuminuria
Original publication
Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care. Published 14 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →